Pulmonary Inflammatory Response in Lethal COVID-19 Reveals Potential Therapeutic Targets and Drugs in Phases III/IV Clinical Trials

Article

Abstract: Background: It is imperative to identify drugs that allow treating symptoms of severe COVID-19. Resp

Palabras claves:

clinical trials, drugs, lethal COVID-19, pulmonary inflammatory response, single nucleus RNA sequencing

Autores:

Alejandro Cabrera-Andrade, Álvaro A. Pérez-Meza, Ana María Gómez-Jaramillo, Andrea Abad-Sojos, Andrea V. Jácome, Andrés López-Cortés, Andy Pérez-Villa, Ángela León-Cáceres, Antonella Vera-Guapi, Ariana León-Sosa, Cevallos-Robalino D., Echeverría-Garcés G., Esteban Ortiz-Prado, Estefanía Abarca, Fernanda Arias-Erazo, Isaac Armendáriz-Castillo, Jennyfer M. García-Cárdenas, Jhommara Bautista, Katherine Simbaña-Rivera, Lourdes Puig San Andrés, Luis Fuenmayor-González, Morillo A., Nieto-Jaramillo K., Nikolaos C. Kyriakidis, P. Guevara-Ramírez, Quiñones L.A., Ramos-Medina M.J., Santiago Xavier Guerrero, Verónica Yumiceba

Fuentes:

scopus